Jo Fearnhead-Wymbs discusses how and why amplifying the patient voice is driving change in the industry for the better.
Christine Phillips looks at how an increase in protectionism across the EU member states with respect to foreign direct investment impacts the life sciences sector.
Historically, Medical Affairs teams have relied on reporting only empirical evidence such as efficacy and tolerability profiles to influence uptake of a new drug or therapy. Here, Ben Routley and Mark Pringle explore the scope for applying behavioral science techniques to improve the impact of client communications.
The two technologies are helping HCPs spread information and collect data in new ways.
Agility and better decisions depend on managing risk and gaining insights from data by prioritizing patient and end-user needs. Companies of all sizes, including GSK, Boehringer-Ingelheim, Sanofi, AstraZeneca, and AbbVie, share best practices.
The digital revolution has brought more efficient ways to reach and touch HCPs.
The importance of enabling customer intelligence at scale.
According to the latest State of Revenue survey of c-suite executives, pharma manufacturers are prioritizing digital transformation while struggling with inflation and supply chain disruptions.
Decentralized tools and technologies will continue to provide new opportunities for patient engagement post-COVID.
Reaching new heights in sustainability a win-win for industry.
Janssen, Johns Hopkins Dermatology’s Ethnic Skin Fellowship Program partnership focuses on improving clinical care and advancing research for skin-of-color patients.
Sy Chyi Yeoh looks at some of the practical considerations faced by Chinese firms looking to expand overseas.
How can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.
Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
The eight key areas biopharma manufacturers must stay on top of when planning and executing alliance agreements with prospective digital health partners.
In a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Understanding of human behavior can aid in avoiding pitfalls during launch.
The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?
Using data visualizations to improve access to payers.
As pharmaceutical market access teams head into 2023, these ten trends detail why evolved preparation, thought, and engagement will be needed to meet post-pandemic marketplace expectations.
New technology is allowing teams to analyze data at faster rates and make decisions much sooner than they previously could.
It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.
With an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.
Organ-on-a-Chip technology has been proven to predict DILI with a higher rate of confidence than traditional in vitro methods and animals. Start protecting human health today.
Delivering on the mission of personalized patient support
The drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.
Merging strengths of traditional behavioral and attitudinal research, capability enables pharmaceutical field teams to prioritize resources, targets, and outreach strategies.
Industry stakeholders must come together to make meaningful changes to reimbursement and establish comprehensive policies that support essential healthcare providers.